EA200701239A1 - 18-метил-9-нор-17-прегн-4-ен-21,17-карболактоны, а также лекарственные препараты, которые их содержат - Google Patents

18-метил-9-нор-17-прегн-4-ен-21,17-карболактоны, а также лекарственные препараты, которые их содержат

Info

Publication number
EA200701239A1
EA200701239A1 EA200701239A EA200701239A EA200701239A1 EA 200701239 A1 EA200701239 A1 EA 200701239A1 EA 200701239 A EA200701239 A EA 200701239A EA 200701239 A EA200701239 A EA 200701239A EA 200701239 A1 EA200701239 A1 EA 200701239A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methyl
atom
hydrogen
carbon atoms
branched chain
Prior art date
Application number
EA200701239A
Other languages
English (en)
Other versions
EA014325B1 (ru
Inventor
Рольф Больманн
Дитер Биттлер
Германн Кюнцер
Петер Эсперлинг
Ханс Петер Мун
Карл-Генрих Фритцемайер
Ульрике Фурманн
Катя Прелле
Борден, (ранее Курц) Штеффен
Original Assignee
Байер Шеринг Фарма Акциенгезельшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36087369&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200701239(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Шеринг Фарма Акциенгезельшафт filed Critical Байер Шеринг Фарма Акциенгезельшафт
Publication of EA200701239A1 publication Critical patent/EA200701239A1/ru
Publication of EA014325B1 publication Critical patent/EA014325B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • C07J53/004—3 membered carbocyclic rings
    • C07J53/008—3 membered carbocyclic rings in position 15/16

Abstract

Настоящее изобретение касается новых 18-метил-19-нор-17-прегн-4-ен-21,17-карболактонов общей формулы Iв которой Z представляет собой атом кислорода, два атома водорода, группировку =NOR или =NNHSOR, причем R означает атом водорода или алкильную группу с прямой или разветвленной цепью, содержащей от 1 до 4 или от 3 до 4 атомов углерода, Rозначает атом водорода, атом галогена, метильную или трифторметильную группу, Rи/или Rможет находиться в α или β и независимо друг от друга означает алкильную группу с прямой или разветвленной цепью, содержащей от 1 до 4 или от 3 до 4 атомов углерода, или Rозначает атом водорода и Rозначает расположенную α или β алкильную группу с прямой или разветвленной цепью, содержащей от 1 до 4 или от 3 до 4 атомов углерода, или Rи Rкаждый означает один атом водорода, или Rи Rвместе означают расположенную α или β метиленовую группу или дополнительную связь. Новые соединения обладают гестагенным и антиминералокортикоидным действием и являются пригодными для получения лекарственных препаратов, например, для пероральной контрацепции и для лечения пре-, пери- и постменопаузальных расстройств.
EA200701239A 2004-12-30 2005-12-30 18-метил-9-нор-17-прегн-4-ен-21,17-карболактоны, а также лекарственные препараты, которые их содержат EA014325B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004063864A DE102004063864A1 (de) 2004-12-30 2004-12-30 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
PCT/EP2005/014205 WO2006072467A1 (de) 2004-12-30 2005-12-30 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische präparate

Publications (2)

Publication Number Publication Date
EA200701239A1 true EA200701239A1 (ru) 2007-12-28
EA014325B1 EA014325B1 (ru) 2010-10-29

Family

ID=36087369

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200701239A EA014325B1 (ru) 2004-12-30 2005-12-30 18-метил-9-нор-17-прегн-4-ен-21,17-карболактоны, а также лекарственные препараты, которые их содержат

Country Status (33)

Country Link
US (1) US20090029953A1 (ru)
EP (1) EP1831240B8 (ru)
JP (1) JP5043681B2 (ru)
KR (1) KR20070093443A (ru)
CN (1) CN101128476B (ru)
AR (1) AR052657A1 (ru)
AU (1) AU2005324055A1 (ru)
BR (1) BRPI0518533A2 (ru)
CA (1) CA2594171C (ru)
CR (1) CR9223A (ru)
CY (1) CY1109498T1 (ru)
DE (2) DE102004063864A1 (ru)
DK (1) DK1831240T3 (ru)
EA (1) EA014325B1 (ru)
ES (1) ES2331322T3 (ru)
GT (1) GT200500394A (ru)
HK (1) HK1112627A1 (ru)
IL (1) IL184288A (ru)
MX (1) MX2007008074A (ru)
MY (1) MY145904A (ru)
NO (1) NO20073257L (ru)
NZ (1) NZ556150A (ru)
PA (1) PA8658401A1 (ru)
PE (2) PE20060853A1 (ru)
PL (1) PL1831240T3 (ru)
PT (1) PT1831240E (ru)
RS (1) RS51128B (ru)
SI (1) SI1831240T1 (ru)
TW (1) TW200635942A (ru)
UA (1) UA90496C2 (ru)
UY (1) UY29320A1 (ru)
WO (1) WO2006072467A1 (ru)
ZA (1) ZA200706254B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027636A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063503A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063495A1 (de) 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063501A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063499A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063500A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
US7960368B2 (en) * 2008-03-05 2011-06-14 Everstra, Inc. Bismethylene-17A carbolactones and related uses
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
EP2367808A4 (en) * 2008-11-25 2012-05-09 Evestra Inc g-LACTONES OF 3- (6,6-ETHYLENE-17β-HYDROXY-3-OXO-17α-PREGEN-4-EENE-17α-YL) PROGESTATIVE PROPIONIC ACID
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2010066349A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Verwendung von 17beta-cyano-19-androst-4-en-derivaten zur herstellung eines arzneimittels in depot-form zur parenteralen anwendung sowie depot-arzneimittel enthaltend 17beta-cyano-19-androst-4-en-derivate zur parenteralen anwendung
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959322A (en) * 1960-09-22 1976-05-25 Herchel Smith Synthesis of 13-alkyl-gon-4-ones
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone

Also Published As

Publication number Publication date
US20090029953A1 (en) 2009-01-29
IL184288A (en) 2011-06-30
WO2006072467A1 (de) 2006-07-13
CY1109498T1 (el) 2014-08-13
CN101128476A (zh) 2008-02-20
EP1831240B8 (de) 2010-02-17
BRPI0518533A2 (pt) 2008-11-25
CA2594171A1 (en) 2006-07-13
JP2008526709A (ja) 2008-07-24
UA90496C2 (ru) 2010-05-11
CA2594171C (en) 2012-10-16
KR20070093443A (ko) 2007-09-18
CN101128476B (zh) 2011-02-09
MY145904A (en) 2012-05-15
SI1831240T1 (sl) 2009-12-31
DK1831240T3 (da) 2009-11-23
AR052657A1 (es) 2007-03-28
NO20073257L (no) 2007-08-29
DE502005007723D1 (de) 2009-08-27
PT1831240E (pt) 2009-10-22
AU2005324055A1 (en) 2006-07-13
RS51128B (sr) 2010-10-31
ES2331322T3 (es) 2009-12-29
PE20060853A1 (es) 2006-09-15
DE102004063864A1 (de) 2006-07-13
NZ556150A (en) 2011-02-25
ZA200706254B (en) 2008-12-31
MX2007008074A (es) 2008-03-10
IL184288A0 (en) 2007-10-31
JP5043681B2 (ja) 2012-10-10
PE20100736A1 (es) 2010-12-03
EA014325B1 (ru) 2010-10-29
GT200500394A (es) 2006-08-01
TW200635942A (en) 2006-10-16
CR9223A (es) 2007-11-23
EP1831240B1 (de) 2009-07-15
PL1831240T3 (pl) 2010-01-29
HK1112627A1 (ru) 2008-09-12
PA8658401A1 (es) 2006-08-03
EP1831240A1 (de) 2007-09-12
UY29320A1 (es) 2006-07-31

Similar Documents

Publication Publication Date Title
EA200701239A1 (ru) 18-метил-9-нор-17-прегн-4-ен-21,17-карболактоны, а также лекарственные препараты, которые их содержат
DE60235019D1 (de) Benzothiazepin-derivate für die behandlung von hyperlipidemia
MA26697A1 (fr) Composes nouveaux inhibiteurs de gsk-3 et compositions pharmaceutiques les contenant
TNSN07070A1 (fr) Composes aminoheteroaryliques enantiomeriquement purs servant d'inhibiteurs de proteine-kinases
ATE438634T1 (de) Benzothiazepinderivate
IS6852A (is) Efnasambönd
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
MA26727A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant
MXPA03011484A (es) Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades.
HUP9901074A2 (hu) Tetrahidropirán és tetrahidrotiopirán aminosavak és ezeket tartalmazó gyógyszerkészítmények
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
PT1294402E (pt) Compostos com um grupo sulfonamida e composicoes farmaceuticas contendo estes compostos
TW200716547A (en) Piperidin-4-yl-amide derivatives
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
DE60230155D1 (de) Verwendung von verzweigtkettigen fettsäuren und ihrer derivate zur schmerzbehandlung
MXPA04005077A (es) Derivados de benzotiazol.
PT982305E (pt) Novos derivados do indano-1-ol proceso para a sua preparacao e as composicoes farmaceuticas que os contem
EA201001011A1 (ru) Производное 15,16-метилен-17-(1'-пропенил)-17-3'-оксидоэстра-4-ен-3-она, его применение и лекарственное средство, содержащее указанное производное
DE602004025119D1 (de) Neue derivate von 4,4'-dithiobis-(3-aminobutan-1-sulfonaten) und diese enthaltende zusammensetzungen
DK601783A (da) Resorcinderivater
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
BRPI0413670A (pt) composição farmacêutica para o tratamento de obesidade ou para facilitar ou promover a perda de peso
ATE314059T1 (de) VERWENDUNG VON ßXYLYLOXY ALKYL AMINESß FÜR DIE BEHANDLUNG VON TINNITUS
NO20062805L (no) Novel indeno (2,1A) indenes and isoindol (2,1-A) indles

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU